- Data management, biostatistics expert adds more than 25 years of experience to support growing demand for periapproval services -
PRINCETON, N.J., June 2 /PRNewswire/ -- Covance Inc. today announced Monte Jarvis as vice president of global data management and biostatistics for periapproval services. With more than 25 years of experience in scientific computing, biostatistics, bioinformatics, programming, and global data management, Jarvis will oversee data management and biostatistics for Phase IIIb/IV clinical studies, patient registries, and observational studies.
“We are excited to welcome Monte and look forward to leveraging his expertise to help increase our access and utilization of emerging technologies and healthcare data structures,” said Hani Zaki, vice president and general manager, periapproval services, Covance. “His extensive experience will improve collaborations and efficiencies to enhance our delivery of REMS and other Phase IIIb/IV services.”
With a diverse background that includes roles in academia, Pharma/biotech, and contract research organizations (CROs), Jarvis will help support increased demand for periapproval services, including risk evaluation and mitigation strategies (REMS), resulting from the Food and Drug Administration Amendment Acts (FDAAA) of 2007.
Jarvis joins Covance from Centocor, where he oversaw biostatistics and data management for the oncology and device divisions. A certified system, network and database administrator, he has helped build scientific and enterprise computing environments and spearheaded corporate adoption of emergent data technologies and standards for pharmaceutical/biotechnology companies and CROs.
Jarvis holds bachelors degrees in Mathematics, Computer Science, and the Humanities and a master’s degree in Demography (Actuarial Statistics). He completed additional coursework at the Wharton School of Business and was a funded PhD candidate at the University of Pennsylvania until leaving academia for industrial research and development. He continues to study new technologies and their application to patient health and wellness.
Covance’s periapproval services include Phase IIIb/IV clinical studies, registries and observational studies, risk management, epidemiology, and product safety services. As the leader in the design and implementation of Risk Evaluation and Mitigation Strategies (REMS), Covance offers innovative tools and methodologies for complete post-approval support.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance’s products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company’s business are based largely on management’s expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company’s ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company’s filings with the Securities and Exchange Commission.Covance and the Covance are registered service marks of Covance in the United States and other countries.
CONTACT: Media Relations, +1-609-419-2466, or Investor Relations,
+1-609-452-4807
Web site: http://www.covance.com/
